Bio­Marin buffs up da­ta on he­mo­phil­ia A gene ther­a­py as FDA de­ci­sion dead­line ap­proach­es

3 years ago
R&D
Cell/Gene Tx

As­traZeneca bets up to $1.8B on Cin­Cor and its ex-Roche drug for hy­per­ten­sion

3 years ago
Deals
Pharma

Up­dat­ed: Ed­i­tas ed­its pipeline, lays off 20% and says bye to CSO to kick off #JPM23 

3 years ago
R&D

At #JPM23, an­oth­er rare dis­ease buy­out as Ipsen ac­quires Al­bireo for $952M

3 years ago
Deals
Pharma

Scoop: Rakuten bil­lion­aire lines up $70M for pho­toim­munother­a­py

3 years ago
Financing
Startups

Kro­nos and Genen­tech ink $20M can­cer dis­cov­ery pact

3 years ago
Deals
R&D

Up­dat­ed: New Ap­ple Tree biotech emerges with an­ti­bod­ies that might pair with Am­gen, Mi­rati's KRAS drugs

3 years ago
Financing
Startups

Ex­clu­sive: Eli Lil­ly boosts in­flam­ma­to­ry dis­ease pipeline, li­cens­es three can­di­dates from TRexBio

3 years ago
Deals

Bil­lion­aire-backed TCR start­up scores its first mar­quee in­dus­try al­liance

3 years ago
R&D

No­var­tis of­floads neu­rode­vel­op­men­tal dis­or­der as­set to small Swiss biotech

3 years ago
Startups
Deals

Qi­a­gen picks up DNA foren­sics com­pa­ny for $150M

3 years ago
Deals
Diagnostics

#JPM23 kicks off with an ac­qui­si­tion as Chiesi inks all-cash $1B+ deal for Am­ryt

3 years ago
Deals
Pharma

Un­pack­ing FDA’s lat­est Alzheimer’s OK; A look at all drugs ap­proved in 2022; Mod­er­na’s deal spree; Pfiz­er ...

3 years ago
Weekly

Doc­tors in­clined to pre­scribe new Alzheimer’s drug de­spite con­cerns

3 years ago
R&D

Emer­gent award­ed $379M+ to sup­ply the DOD with a skin de­con­t­a­m­i­na­tion lo­tion

3 years ago
Deals
Pharma

Pre­ci­sion Bio­Sciences gets pos­i­tive CMC feed­back for al­lo­gene­ic CAR-T can­di­date

3 years ago
FDA+
Manufacturing

Ei­sai prices Alzheimer's drug at $26,500, be­low part­ner Bio­gen's Aduhelm

3 years ago
Pharma
FDA+

BioN­Tech inks part­ner­ship with UK to speed up re­cruit­ment of mR­NA can­cer tri­als

3 years ago
Pharma

FDA grants pri­or­i­ty re­views for Pfiz­er's Pre­vnar 20 for kids and Roche lym­phoma can­di­date

3 years ago
Pharma
FDA+

Break­ing: FDA clears sec­ond Alzheimer's drug in 'foun­da­tion­al spark' for field

3 years ago
R&D
Pharma

Brands in de­mand: Keytru­da, Dupix­ent and Ozem­pic lead 2023 new sales pre­dic­tions — Eval­u­ate re­port

3 years ago
Pharma
Marketing

Amolyt hauls in €130M round to fund PhI­II tri­al of hy­poparathy­roidism drug

3 years ago
Financing

Three biotechs start the year with job cuts; Re­gen­eron ex­pands deal with blue­bird spin­out 

3 years ago
News Briefing

Tu­mor gene ther­a­py de­vel­op­er re­brands, emerges with $30M from blue-chip in­vestors

3 years ago
Financing
First page Previous page 405406407408409410411 Next page Last page
A service from the Financial Times